Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity

키워드

참고문헌 (113)

1. Vantourout P, "Six-of-the-best : unique contributions of γδ T cells to immunology", Nat Rev Immunol, 13, pp.88~100 (2013)
2. Adams EJ, "Human gamma delta T cells : evolution and ligand recognition", Cell Immunol, 296, pp.31~40 (2015)
3. Chien YH, "γδ T cells : first line of defense and beyond", Annu Rev Immunol, 32, pp.121~155 (2014)
4. Stolk D, "Positive & negative roles of innate effector cells in controlling cancer progression", Front Immunol, 9, pp.1990~ (2018)
5. Girardi M, "Regulation of cutaneous malignancy by gammadelta T cells", Science, 294, pp.605~609 (2001)
6. Mishra R, "NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors", PLoS Pathog, 6, pp.e1000924~ (2010)
7. Zhao Y, "Gamma-delta (γδ) T cells: friend or foe in cancer development?", J Transl Med, 16, pp.3~ (2018)
8. Barrow AD, "The natural cytotoxicity receptors in health and disease", Front Immunol, 10, pp.909~ (2019)
9. Wrobel P, "Lysis of a broad range of epithelial tumour cells by human gamma delta T cells : involvement of NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition", Scand J Immunol, 66, pp.320~328 (2007)
10. Braza MS, "Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes : from the bench to the bedside", Br J Haematol, 160, pp.123~132 (2013)
11. Hannani D, "Harnessing γδ T cells in anticancer immunotherapy", Trends Immunol, 33, pp.199~206 (2012)
12. Kunzmann V, "Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy : results from a prospective phase I", II trial, 2012, pp.35, 205~213
13. Nicol AJ, "Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours", Br J Cancer, 105, pp.778~786 (2011)
14. Rei M, "The emerging protumor role of γδ T lymphocytes : implications for cancer immunotherapy", Cancer Res, 75, pp.798~802 (2015)
15. Fournié JJ, "What lessons can be learned from γδ T cell-based cancer immunotherapy trials", Cell Mol Immunol, 10, pp.35~41 (2013)
16. Lo Presti E, "Current advances in γδ T cell-based tumor immunotherapy", Front Immunol, 8, pp.1401~ (2017)
17. Xiang Z, "Dual face of Vγ9Vδ2-T cells in tumor immunology : anti-versus pro-tumoral activities", Front Immunol, 8, pp.1041~ (2017)
18. Turchinovich G, "T cell receptor signalling in γδ cell development : strength isn't everything", Trends Immunol, 32, pp.567~573 (2011)
19. Baker JE, "Developmentally programmed rearrangement of T cell receptor Vgamma genes is controlled by sequences immediately upstream of the Vgamma genes", Immunity, 9, pp.159~168 (1998)
20. Chodaczek G, "Body-barrier surveillance by epidermal γδ TCRs", Nat Immunol, 13, pp.272~282 (2012)
21. Boyden LM, "Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells", Nat Genet, 40, pp.656~662 (2008)
22. Bonneville M, "Gammadelta T cell effector functions : a blend of innate programming and acquired plasticity", Nat Rev Immunol, 10, pp.467~478 (2010)
23. O'Brien RL, "Gammadelta T cell subsets : a link between TCR and function", Semin Immunol, 22, pp.193~198 (2010)
24. Vermijlen D, "Ontogeny of innate T lymphocytes-some innate lymphocytes are more innate than others", Front Immunol, 5, pp.486~ (2014)
25. Lanier LL, "Presence of Ti(WT31)negative T lymphocytes in normal blood and thymus", Nature, 324, pp.268~270 (1986)
26. Morita CT, "TCR usage and functional capabilities of human gamma delta T cells at birth", J Immunol, 153, pp.3979~3988 (1994)
27. Vermijlen D, "Human cytomegalovirus elicits fetal gammadelta T cell responses in utero", J Exp Med, 207, pp.807~821 (2010)
28. Parker CM, "Evidence for extrathymic changes in the T cell receptor gamma", delta repertoire, 1990, pp.171, 1597~1612
29. Cairo C, "Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Côte d'Ivoire", Immunology, 124, pp.380~387 (2008)
30. Moens E, "IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17", J Leukoc Biol, 89, pp.743~752 (2011)
31. De Rosa SC, "Ontogeny of gamma delta T cells in humans", J Immunol, 172, pp.1637~1645 (2004)
32. Cruz MS, "Human αβ and γδ T cells in skin immunity and disease", Front Immunol, 9, pp.1304~ (2018)
33. Allison TJ, "Structure of a human gammadelta T-cell antigen receptor", Nature, 411, pp.820~824 (2001)
34. Legut M, "The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy", Cell Mol Immunol, 12, pp.656~668 (2015)
35. Davey MS, "Recasting human Vδ1 lymphocytes in an adaptive role", Trends Immunol, 39, pp.446~459 (2018)
36. Pizzolato G, "Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes", Proc Natl Acad Sci U S A, 116, pp.11906~11915 (2019)
37. Kazen AR, "Evolution of the V, D, and J gene segments used in the primate gammadelta T-cell receptor reveals a dichotomy of conservation and diversity", Proc Natl Acad Sci U S A, 108, pp.E332~ (2011)
38. Vavassori S, "Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells", Nat Immunol, 14, pp.908~916 (2013)
39. Simões AE, "Molecular determinants of target cell recognition by human γδ T cells", Front Immunol, 9, pp.929~ (2018)
40. Hayes SM, "Stoichiometry of the murine gammadelta T cell receptor", J Exp Med, 203, pp.47~52 (2006)
41. Malissen M, "Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene", EMBO J, 14, pp.4641~4653 (1995)
42. Dave VP, "CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage", EMBO J, 16, pp.1360~1370 (1997)
43. Haks MC, "The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages", EMBO J, 17, pp.1871~1882 (1998)
44. Hayes SM, "Distinct structure and signaling potential of the gamma delta TCR complex", Immunity, 16, pp.827~838 (2002)
45. Siegers GM, "Different composition of the human and the mouse gammadelta T cell receptor explains different phenotypes of CD3gamma and CD3delta immunodeficiencies", J Exp Med, 204, pp.2537~2544 (2007)
46. Recio MJ, "Differential biological role of CD3 chains revealed by human immunodeficiencies", J Immunol, 178, pp.2556~2564 (2007)
47. Jensen KD, "Thymic selection determines gammadelta T cell effector fate : antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma", Immunity, 29, pp.90~100 (2008)
48. Taghon T, "Developmental and molecular characterization of emerging beta-and gammadelta-selected pre-T cells in the adult mouse thymus", Immunity, 24, pp.53~64 (2006)
49. Lafont V, "Plasticity of γδ T cells : impact on the anti-tumor response", Front Immunol, 5, pp.622~ (2014)
50. Hayday A, "Casting new light on the TCR", Nat Immunol, 13, pp.209~211 (2012)
51. Parham P, "Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution", Nat Rev Immunol, 13, pp.133~144 (2013)
52. Wensveen FM, "NKG2D : a master regulator of immune cell responsiveness", Front Immunol, 9, pp.441~ (2018)
53. Ribot JC, "Searching for"signal 2" : costimulation requirements of γδ T cells", Cell Mol Life Sci, 68, pp.2345~2355 (2011)
54. Testi R, "Functional expression of CD28 on T cell antigen receptor gamma", delta-bearing T lymphocytes, 1989, pp.19, 185~188
55. Penninger JM, "Alloreactive gamma delta thymocytes utilize distinct costimulatory signals from peripheral T cells", J Immunol, 155, pp.3847~3855 (1995)
56. Hamann D, "Phenotypic and functional separation of memory and effector human CD8+ T cells", J Exp Med, 186, pp.1407~1418 (1997)
57. De Rosa SC, "Vdelta1 and Vdelta2 gammadelta T cells express distinct surface markers and might be developmentally distinct lineages", J Leukoc Biol, 70, pp.518~526 (2001)
58. Seelige R, "Mechanisms regulating immune surveillance of cellular stress in cancer", Cell Mol Life Sci, 75, pp.225~240 (2018)
59. Bassani B, "Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects", Cancers (Basel), 11, pp.461~ (2019)
60. O'Donnell JS, "Cancer immunoediting and resistance to T cell-based immunotherapy", Nat Rev Clin Oncol, 16, pp.151~167 (2019)
61. Runa F, "Tumor microenvironment heterogeneity : challenges and opportunities", Curr Mol Biol Rep, 3, pp.218~229 (2017)
62. Nakamura K, "Targeting cancer-related inflammation in the era of immunotherapy", Immunol Cell Biol, 95, pp.325~332 (2017)
63. Lo Presti E, "γδ cells and tumor microenvironment : a helpful or a dangerous liason", J Leukoc Biol, 103, pp.485~492 (2018)
64. Paul S, "Regulatory and effector functions of gamma-delta(γδ)T cells and their therapeutic potential in adoptive cellular therapy for cancer", Int J Cancer, 139, pp.976~985 (2016)
65. Silva-Santos B, "γδ T cells in cancer", Nat Rev Immunol, 15, pp.683~691 (2015)
66. Lee M, "Preferential infiltration of unique Vγ9Jγ2-Vδ2 T cells into glioblastoma multiforme", Front Immunol, 10, pp.555~ (2019)
67. Cordova A, "Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas", PLoS One, 7, pp.e49878~ (2012)
68. Deniger DC, "Clinical applications of gamma delta T cells with multivalent immunity", Front Immunol, 5, pp.636~ (2014)
69. Davey MS, "Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance", Nat Commun, 8, pp.14760~ (2017)
70. Sandstrom A, "The intracellular B30. 2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells", Immunity, 40, pp.490~500 (2014)
71. Yang Y, "A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vγ9Vδ2 T cell activation", Immunity, 50, pp.1043~1053 (2019)
72. Sebestyen Z, "RhoB mediates phosphoantigen recognition by Vγ9Vδ2 T cell receptor", Cell Reports, 15, pp.1973~1985 (2016)
73. Rigau M, "Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells", Science, 367, pp.eaay5516~ (2020)
74. Dai Y, "Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor", virus immunity, 2012, pp.287, 16812~16819
75. Tyler CJ, "Human Vγ9", Vδ2 T cells : innate adaptors of the immune system, 2015, pp.296, 10~21
76. Uldrich AP, "CD1d-lipid antigen recognition by the γδ TCR", Nat Immunol, 14, pp.1137~1145 (2013)
77. Wu D, "Human γδT-cell subsets and their involvement in tumor immunity", Cell Mol Immunol, 14, pp.245~253 (2017)
78. Le Nours J, "A class of γδ T cell receptors recognize the underside of the antigen-presenting molecule MR1", Science, 366, pp.1522~1527 (2019)
79. Hudspeth K, "Natural cytotoxicity receptors : broader expression patterns and functions in innate and adaptive immune cells", Front Immunol, 4, pp.69~ (2013)
80. Almeida AR, "Delta one t cells for immunotherapy of chronic lymphocytic leukemia : clinical-grade expansion", differentiation and preclinical proof of concept, 2016, pp.22, 5795~5804
81. Willcox CR, "Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor", Nat Immunol, 13, pp.872~879 (2012)
82. Deniger DC, "Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies", Clin Cancer Res, 20, pp.5708~5719 (2014)
83. Li Z, "IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas", Fas ligand pathway, 2011, pp.11, 496~503
84. Tawfik D, "TRAIL-receptor 4 modulates γδ T cell-cytotoxicity toward cancer cells", Front Immunol, 10, pp.2044~ (2019)
85. Pauza CD, "Gamma delta T cell therapy for cancer : it is good to be local", Front Immunol, 9, pp.1305~ (2018)
86. Angelini DF, "FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways", Blood, 104, pp.1801~1807 (2004)
87. Gentles AJ, "The prognostic landscape of genes and infiltrating immune cells across human cancers", Nat Med, 21, pp.938~945 (2015)
88. Meraviglia S, "Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer", OncoImmunology, 6, pp.e1347742~ (2017)
89. 김지성, "Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells", Immune Network, 16(2), pp.99~108 (2016), 대한면역학회[DOI]
90. 박찬호, "Expansion and Sub-Classification of T Cell-Dependent Antibody Responses to Encompass the Role of Innate-Like T Cells in Antibody Responses", Immune Network, 18(5), pp.1~12 (2018), 대한면역학회[DOI]
91. Gu-Trantien C, "CD4+ follicular helper T cell infiltration predicts breast cancer survival", J Clin Invest, 123, pp.2873~2892 (2013)
92. Caccamo N, "Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells", Blood, 118, pp.129~138 (2011)
93. Thommen DS, "T cell dysfunction in cancer", Cancer Cell, 33, pp.547~562 (2018)
94. Xia A, "T cell dysfunction in cancer immunity and immunotherapy", Front Immunol, 10, pp.1719~ (2019)
95. Kim PS, "Features of responding T cells in cancer and chronic infection", Curr Opin Immunol, 22, pp.223~230 (2010)
96. Meraviglia S, "Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy", Curr Mol Med, 10, pp.719~726 (2010)
97. Zou C, "γδ T cells in cancer immunotherapy", Oncotarget, 8, pp.8900~8909 (2017)
98. Wu D, "Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer", OncoImmunology, 4, pp.e992749~ (2015)
99. Siegers GM, "Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells", Cytotherapy, 13, pp.753~764 (2011)
100. Gonçalves-Sousa N, "Inhibition of murine gammadelta lymphocyte expansion and effector function by regulatory alphabeta T cells is cell-contact-dependent and sensitive to GITR modulation", Eur J Immunol, 40, pp.61~70 (2010)
101. Li W, "Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2", J Immunother, 33, pp.287~296 (2010)
102. Li W, "Modulation of innate immunity by IL-18", J Reprod Immunol, 83, pp.101~105 (2009)
103. Van Acker HH, "Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells", J Hematol Oncol, 9, pp.101~ (2016)
104. Wang X, "IL-36γ transforms the tumor microenvironment and promotes type 1 lymphocyte-mediated antitumor immune responses", Cancer Cell, 28, pp.296~306 (2015)
105. Thedrez A, "IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy", J Immunol, 182, pp.3423~3431 (2009)
106. Chen J, "Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes", Int Arch Allergy Immunol, 125, pp.256~263 (2001)
107. Choudhary A, "Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma", J Immunol, 154, pp.3932~3940 (1995)
108. Couzi L, "Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation", J Am Soc Nephrol, 21, pp.181~188 (2010)
109. Knight A, "CMV-independent lysis of glioblastoma by ex vivo expanded", activated Vδ1+ γδ T cells, 2013, pp.8, e68729~
110. Knight A, "Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells", Cytotherapy, 14, pp.1110~1118 (2012)
111. Lança T, "Protective role of the inflammatory CCR2", CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds, 2013, pp.190, 6673~6680
112. Peng G, "Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway", Immunity, 27, pp.334~348 (2007)
113. Mao Y, "A new effect of IL-4 on human γδ T cells : promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells", Cell Mol Immunol, 13, pp.217~228 (2016)

관련 논문AI추천